RC-88 |
RC-88 |
Phase 2 Clinical |
RemeGen Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
Details
|
iCasp9M28z |
iCasp9M28z |
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center |
Small Cell Lung Carcinoma; Pleural Diseases; Mesothelioma; Breast Neoplasms; Lung Neoplasms; Neoplasm Metastasis |
Details
|
Anetumab ravtansine |
BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 |
Phase 2 Clinical |
Bayer AG, Morphosys Ag |
Ovarian Neoplasms; Solid tumours; Cystadenocarcinoma, Serous; Neoplasms; Pancreatic Neoplasms; Mesothelioma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Carcinoma, Endometrioid |
Details
|
Gavocabtagene autoleucel |
TC-210 |
Phase 2 Clinical |
Tcr2 Therapeutics Inc |
Ovarian Neoplasms; Mesothelioma; Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
LMB-100 |
LMB-100; RG-7787; RO-6927005 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Neoplasms, Mesothelial; Carcinoma; Small Cell Lung Carcinoma; Adenocarcinoma of Lung; Neoplasms; Pancreatic Neoplasms; Mesothelioma; Cholangiocarcinoma; Lung Neoplasms; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung |
Details
|
anti-MESO CAR-T cells (Zhejiang University) |
UCLM802; UCLM-802 |
Phase 2 Clinical |
Zhejiang University, Hrain Biotechnology Co Ltd |
Ovarian Neoplasms; Solid tumours |
Details
|
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Neoplasms |
Details
|
HPN-536 |
HPN-536 |
Phase 2 Clinical |
Harpoon Therapeutics |
Neoplasms |
Details
|
Autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
CD40 ligand expressing MSLN-CAR T cells |
|
Phase 2 Clinical |
Pla General Hospital |
Solid tumours |
Details
|
A2B-694 |
A2B-694; A2B694 |
Phase 2 Clinical |
A2 Biotherapeutics Inc |
Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Mesothelioma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
RNA-Meso-CIR-T |
RNA-Meso-CIR-T |
Phase 1 Clinical |
Novartis Pharma Ag, University Of Pennsylvania |
Mesothelioma |
Details
|
CART-meso |
CART-meso |
Phase 1 Clinical |
Novartis Pharma Ag, University Of Pennsylvania |
Ovarian Neoplasms; Carcinoma; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Mesothelioma; Breast Neoplasms; Fallopian Tube Neoplasms |
Details
|
ABBV-428 |
ABBV-428; ABBV428 |
Phase 1 Clinical |
Abbvie Inc |
Solid tumours |
Details
|
Anti-mesothelin thorium-227 labeled antibody chelator conjugate |
BAY-2287411 |
Phase 1 Clinical |
Bayer AG |
Ovarian Neoplasms; Mesothelioma; Carcinoma, Pancreatic Ductal |
Details
|
AB-1015 |
AB-1015 |
Phase 1 Clinical |
Arsenal Biosciences Inc |
Ovarian Neoplasms; Carcinoma, Ovarian Epithelial |
Details
|
SynKIR-110 |
SynKIR™-110; SynKIR-meso |
Phase 1 Clinical |
Verismo Therapeutics Inc |
Ovarian Neoplasms; Mesothelioma; Cholangiocarcinoma |
Details
|
KT-032 |
KT-032 |
Phase 1 Clinical |
Nanjing Kati Medical Technology Co Ltd |
Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Mesothelioma |
Details
|
JNJ-79032421 |
JNJ-79032421; JNJ-2421 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Solid tumours |
Details
|
YL-215 |
YL215; YL-215 |
Phase 1 Clinical |
MediLink Therapeutics Co Ltd |
Solid tumours |
Details
|
GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Guangzhou Medical University |
Solid tumours; Liver Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Mesothelioma; Lung Neoplasms |
Details
|
AMG 305 |
AMG-305; AMG 305 |
Phase 1 Clinical |
Amgen Inc |
Solid tumours |
Details
|
UCMYM-802 |
UCMYM802; UCMYM-802 |
Phase 1 Clinical |
Shanghai Youti zjisheng Biomedicine Co Ltd |
Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Pancreatic Neoplasms; Mesothelioma; Breast Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms |
Details
|
HBM-9033 |
HBM-9033; HBM9033 |
Phase 1 Clinical |
Nona Biosciences |
Solid tumours |
Details
|
Anti-mesothelin CAR T cell therapy (UTC Therapeutics Inc) |
|
Phase 1 Clinical |
UTC Therapeutics Inc |
Solid tumours |
Details
|
LD013 CAR T-cell therapy (Nanjing Landun Biotechnology) |
LD013; LD-013 |
Phase 1 Clinical |
Nanjing Landun Biotechnology Co Ltd |
Ovarian Neoplasms; Solid tumours |
Details
|
RD-138 |
RD-138 |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Multiple Myeloma |
Details
|
RD-133 |
RD133 |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Solid tumours; Neoplasms |
Details
|
PM-3006 |
PM-3006 |
Phase 1 Clinical |
Biotheus Inc |
|
Details
|
Autologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville) |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center |
Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal |
Details
|
Anti-mesothelin CAR-NK cell therapy(Guojianchengnuo) |
ALF-101 |
Phase 1 Clinical |
Guojianchengnuo Biotechnology (Beijing) Co Ltd |
Carcinoma, Ovarian Epithelial |
Details
|
Inezetamab |
AMG-994 |
Phase 1 Clinical |
Amgen Inc |
Solid tumours |
Details
|
αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd) |
BZDS1901; BZDS-1901; BZD1901 |
Phase 1 Clinical |
Shanghai Cell Therapy Group Co Ltd |
Ovarian Neoplasms; Solid tumours; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
KD-021 |
KD-021 |
Phase 1 Clinical |
Nanjing Kaedi Biotechnology Co Ltd |
Neoplasms |
Details
|
Anti-mesothelin CAR-T (Pregene) |
|
Clinical |
Pregene (Shenzhen) Biotechnology Co Ltd |
Hydrothorax |
Details
|
TCR-like CAR-T Cell Therapy(Zhongda Hospital Southeast University) |
|
|
Zhongda Hospital Southeast University |
|
Details
|
Mesothelin-CAR-T Cells(Fapon Biopharma) |
FP-002 |
|
Fapon Biotech Inc |
|
Details
|